GlassScriptPhysician profile
Ravish Parekh
NPI 1144541442
$67,780.75
in general payments reported to CMS, 2019-2025
29 companies · $35K in 2025
The $35K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $423 · 2021: $475 · 2022: $988 · 2023: $1,520 · 2024: $29K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Food and Beverage: $5,031 · Consulting Fee: $475 · Travel and Lodging: $194 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,450.00 |
| Food and Beverage | $5,030.85 |
| Consulting Fee | $475.00 |
| Travel and Lodging | $194.35 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $37,505.14 | 2024-2025 | Omvoh |
| Abbvie INC. | $26,014.47 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,265.70 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $622.96 | 2020-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $454.06 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $428.35 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $250.65 | 2023-2025 | Zenpep |
| Celgene Corporation | $219.06 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $192.90 | 2019-2025 | |
| Ardelyx, INC. | $147.07 | 2022-2025 | Ibsrela |
| Cardiovascular Systems INC. | $129.73 | 2019 | |
| Ferring Pharmaceuticals INC. | $93.54 | 2019-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $59.58 | 2022-2023 | |
| Ucb, INC. | $55.32 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $42.96 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $42.38 | 2025 | Rezdiffra |
| Capsovision, INC. | $38.25 | 2024-2025 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $33.69 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $29.68 | 2020 | |
| Allergan, INC. | $25.90 | 2019 | |
| Travere Therapeutics, INC. | $19.71 | 2019 | |
| Genzyme Corporation | $18.26 | 2022 | |
| Novo Nordisk INC | $16.71 | 2019 | |
| Sandoz INC. | $16.05 | 2023 | Hyrimoz |
| Ipsen Biopharmaceuticals, INC | $14.90 | 2025 | Iqirvo |
| Organon LLC | $14.82 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $14.57 | 2023 | Dupixent |
| Qol Medical, LLC | $14.34 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravish Parekh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.